Anzeige
Mehr »
Sonntag, 08.06.2025 - Börsentäglich über 12.000 News
5-Dollar-Kupfer. KI-Infrastruktur. Energiewende. Vizsla Copper hat die Pfunde im Boden, die jetzt zählen.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von FierceBiotech

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
05.05.Several months after Exscientia merger, AI biotech outfit Recursion reworks pipeline
05.05.Immutep takes immunotherapy a step further with 'impressive' survival data from Keytruda combo
05.05.Deerfield unveils $600M for emerging healthcare therapeutics and tech
02.05.Vertex discontinues AAV research for gene therapies
02.05.Trump plans $18B NIH budget cut, wants 27 centers consolidated into 5
02.05.FDA frees Amgen's phase 1 obesity asset from clinical trial hold
02.05.UK unveils £1B plan to become leading cancer research hub just outside the Golden Triangle
02.05.FDA delays decision date on Cytokinetics' heart drug to year-end in unusual safety program back-and-forth
02.05.Pliant Therapeutics cuts workforce by 45% after bexotegrast trial safety woes
30.04.Biopharma VC financing fell 20% in Q1 compared to '24: GlobalData
30.04.Cellectar is seeking strategic alternatives, sinking stock
30.04.Investor pressures Acelyrin to exit Alumis merger and liquidate, slams 'inexplicable' process
30.04.Novartis pays $800M upfront to buy Regulus for phase 3-ready kidney drug
30.04.Entrada lays off 20% of staff weeks after having FDA hold lifted
29.04.Ono Pharma lays off 83 staffers at Cambridge site
29.04.Eli Lilly pens Creyon Bio AI oligonucleotide pact with $1B in biobucks on the table
29.04.FDA misses PDUFA date for Stealth's ultra-rare disease candidate, delaying approval decision-again
29.04.Octagon shuts down after R&D challenges put it behind the 8 ball
29.04.AstraZeneca culls a Lilly-partnered Alzheimer's drug alongside 2 other neuroscience meds in Q1 clear-out
29.04.Novartis axes osteoarthritis asset and radioligand therapy after seeing clinical data
28.04.Biohaven, after setbacks, sees shares jump with Oberland Capital funding agreement worth up to $600M
28.04.Ferrer inks licensing deal worth up to €500M for Prilenia's ALS asset
28.04.HHS lifts stop work order on Vaxart's COVID-19 trial, continues funding for the 10,000-participant study
28.04.Novo Holdings dials back investment as Trump stymies economic forecasters
28.04.Tonix Pharmaceuticals culls cocaine intoxication trial amid enrollment woes